Literature DB >> 20001238

Prognostic significance of acute renal injury in acute tumor lysis syndrome.

Michael Darmon1, Isabelle Guichard, François Vincent, Benoit Schlemmer, Elie Azoulay.   

Abstract

Acute tumor lysis syndrome (ATLS) caused by the destruction of malignant cells leads to metabolic abnormalities, which may either remain isolated (biological ATLS) or subsequently lead to renal dysfunction (clinical ATLS). We compared hospital and 6-month survival in patients with ATLS with hematological malignancies with or without acute renal injury. Sixty-three patients (median age, 50 years; range, 32-64) were included with ATLS. Twenty-eight had no ARI (including 17 (61%) who subsequently required dialysis) whereas 35 had an ATLS-related ARI (including 31 (89%) who required dialysis). Acute leukemia (n = 28) and lymphoma (n = 30) were the main malignancies. All patients had high tumor burdens. Hospital and 6-month mortality rates were significantly lower in patients without ARI (7% and 21%, respectively) than in the ATLS-related renal injury group (51% and 66%). After adjustment for acute disease severity, presence of ARI at ICU admission was associated with higher hospital mortality (odds ratio, 10.41; 95% confidence interval, 2.01-19.170; p = 0.005) and 6-month mortality (odds ratio, 5.61; 95% confidence interval, 1.64-54.66; p = 0.006), compared to patients without renal injury. Our study suggests that in patients with ATLS, ICU management when acute renal injury is present is associated with higher short- and long-term mortality.

Entities:  

Mesh:

Year:  2010        PMID: 20001238     DOI: 10.3109/10428190903456959

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  20 in total

1.  Febuxostat and tumor lysis syndrome: an indication that remains unclear.

Authors:  F Vincent; A Dupré; C Mousseaux; C Bornstain; M Darmon
Journal:  Int J Clin Oncol       Date:  2016-12-01       Impact factor: 3.402

Review 2.  Tumor lysis syndrome: new challenges and recent advances.

Authors:  F Perry Wilson; Jeffrey S Berns
Journal:  Adv Chronic Kidney Dis       Date:  2014-01       Impact factor: 3.620

3.  Rasburicase-induced Hemolytic Anemia in an Adolescent With Unknown Glucose-6-Phosphate Dehydrogenase Deficiency.

Authors:  Manzilat Akande; Anthony N Audino; Joseph D Tobias
Journal:  J Pediatr Pharmacol Ther       Date:  2017 Nov-Dec

4.  Understanding tumor lysis syndrome.

Authors:  Lara Zafrani; Emmanuel Canet; Michael Darmon
Journal:  Intensive Care Med       Date:  2019-09-13       Impact factor: 17.440

5.  Spontaneous tumour lysis syndrome secondary to the transformation of chronic myelomonocytic leukaemia into acute myeloid leukaemia.

Authors:  Alexander Langridge; Kathryn Musgrave; Yogesh Upadhye
Journal:  BMJ Case Rep       Date:  2016-03-09

6.  In-Hospital Outcomes of Tumor Lysis Syndrome: A Population-Based Study Using the National Inpatient Sample.

Authors:  Urshila Durani; Nilay D Shah; Ronald S Go
Journal:  Oncologist       Date:  2017-09-13

7.  [Leukostasis and tumor lysis: important complications of hyperleukocytosis].

Authors:  P Schellongowski; T Staudinger
Journal:  Internist (Berl)       Date:  2013-09       Impact factor: 0.743

8.  Intensive care of the cancer patient: recent achievements and remaining challenges.

Authors:  Elie Azoulay; Marcio Soares; Michael Darmon; Dominique Benoit; Stephen Pastores; Bekele Afessa
Journal:  Ann Intensive Care       Date:  2011-03-23       Impact factor: 6.925

Review 9.  Fluid Stewardship of Maintenance Intravenous Fluids.

Authors:  John R Carr; W Anthony Hawkins; Andrea Sikora Newsome; Susan E Smith; Clemmons Amber B; Christopher M Bland; Trisha N Branan
Journal:  J Pharm Pract       Date:  2021-04-08

10.  Interleukin 18 as a marker of chronic nephropathy in children after anticancer treatment.

Authors:  Małgorzata Zubowska; Krystyna Wyka; Wojciech Fendler; Wojciech Młynarski; Beata Zalewska-Szewczyk
Journal:  Dis Markers       Date:  2013-11-27       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.